172 related articles for article (PubMed ID: 27326246)
1. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era.
Kim ST; Lee SJ; Park SH; Park JO; Lim HY; Kang WK; Lee J; Park YS
J Cancer; 2016; 7(9):1044-8. PubMed ID: 27326246
[TBL] [Abstract][Full Text] [Related]
2. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
3. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
Kim ST; Ha SY; Lee S; Ahn S; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim KM; Park YS
J Cancer; 2016; 7(5):484-9. PubMed ID: 26958083
[TBL] [Abstract][Full Text] [Related]
4. ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS.
Tirosh A; Killian JK; Zhu YJ; Petersen D; Walling J; Mor-Cohen R; Neychev V; Stevenson H; Keutgen XM; Patel D; Nilubol N; Meltzer P; Kebebew E
Endocr Pract; 2019 Jun; 25(6):580-588. PubMed ID: 30865533
[No Abstract] [Full Text] [Related]
5. The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.
Yoon SE; Kim JH; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
J Cancer; 2019; 10(14):3140-3144. PubMed ID: 31289584
[No Abstract] [Full Text] [Related]
6. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.
Watson C; Tallentire CW; Ramage JK; Srirajaskanthan R; Leeuwenkamp OR; Fountain D
World J Gastroenterol; 2020 Jul; 26(25):3686-3711. PubMed ID: 32742136
[TBL] [Abstract][Full Text] [Related]
7. Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma.
Knappskog S; Grob T; Venizelos A; Amstutz U; Hjortland GO; Lothe IM; Kersten C; Hofsli E; Sundlöv A; Elvebakken H; Garresori H; Couvelard A; Svensson J; Sorbye H; Perren A
JCO Precis Oncol; 2023 Feb; 7():e2200336. PubMed ID: 36753687
[TBL] [Abstract][Full Text] [Related]
8. Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry.
Palepu J; Shrikhande SV; Bhaduri D; Shah RC; Sirohi B; Chhabra V; Dhar P; Sastry R; Sikora S
Indian J Gastroenterol; 2017 Nov; 36(6):445-451. PubMed ID: 29457213
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
Özaslan E; Demir S; Karaca H; Güven K
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
[TBL] [Abstract][Full Text] [Related]
10. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
11. [Well differentiated grade 3 gastroenteropancreatic neuroendocrine tumors:new insights into diagnosis and therapeutic strategy].
Fan ZY; Shi M; Yang J; Li YZ; Su P; Wang X; Zhan HX
Zhonghua Wai Ke Za Zhi; 2021 Aug; 59(8):704-710. PubMed ID: 34192864
[TBL] [Abstract][Full Text] [Related]
12. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.
Girardi DM; Silva ACB; Rêgo JFM; Coudry RA; Riechelmann RP
Cancer Treat Rev; 2017 May; 56():28-35. PubMed ID: 28456055
[TBL] [Abstract][Full Text] [Related]
13. Gastroenteropancreatic endocrine tumors.
Meeker A; Heaphy C
Mol Cell Endocrinol; 2014 Apr; 386(1-2):101-20. PubMed ID: 23906538
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
15. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study.
O'Connor JM; Marmissolle F; Bestani C; Pesce V; Belli S; Dominichini E; Mendez G; Price P; Giacomi N; Pairola A; Loria FS; Huertas E; Martin C; Patane K; Poleri C; Rosenberg M; Cabanne A; Kujaruk M; Caino A; Zamora V; Mariani J; Dioca M; Parma P; Podesta G; Andriani O; Gondolesi G; Roca E
Mol Clin Oncol; 2014 Sep; 2(5):673-684. PubMed ID: 25054030
[TBL] [Abstract][Full Text] [Related]
16. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
17. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study.
; Cho MY; Kim JM; Sohn JH; Kim MJ; Kim KM; Kim WH; Kim H; Kook MC; Park DY; Lee JH; Chang H; Jung ES; Kim HK; Jin SY; Choi JH; Gu MJ; Kim S; Kang MS; Cho CH; Park MI; Kang YK; Kim YW; Yoon SO; Bae HI; Joo M; Moon WS; Kang DY; Chang SJ
Cancer Res Treat; 2012 Sep; 44(3):157-65. PubMed ID: 23091441
[TBL] [Abstract][Full Text] [Related]
18. PRRT genomic signature in blood for prediction of
Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Cwikla J; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1155-1169. PubMed ID: 29484451
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.
Guo LJ; Wang CH; Tang CW
Asia Pac J Clin Oncol; 2016 Sep; 12(3):284-8. PubMed ID: 27170574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
